Arcadia Biosciences (NASDAQ:RKDA) Issues Earnings Results

Arcadia Biosciences (NASDAQ:RKDA) issued its quarterly earnings results on Thursday. The basic materials company reported ($2.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($1.53), FiscalAI reports. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $1.90 million. Arcadia Biosciences had a negative return on equity of 113.73% and a negative net margin of 195.94%.

Arcadia Biosciences Stock Performance

Shares of RKDA traded down $0.13 during midday trading on Thursday, hitting $0.57. 691,056 shares of the stock traded hands, compared to its average volume of 123,671. The firm has a market capitalization of $1.37 million, a PE ratio of -0.10 and a beta of 0.56. Arcadia Biosciences has a 1-year low of $0.50 and a 1-year high of $6.71. The business’s 50 day moving average price is $0.73 and its two-hundred day moving average price is $1.21.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Arcadia Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.